Dr. Daniel Hampshire BSc PhD
Honorary Research Fellow
Department of Infection, Immunity & Cardiovascular Disease
University of Sheffield
Beech Hill Road
Tel: +44 (0)114 215 9500
Fax: +44 (0)114 271 1863
Post-PhD, I have worked within the Haemostasis Research Group (University of Sheffield) with Prof. Anne Goodeve and Prof. Ian Peake for the past 12 years funded by a USA National Institutes of Health Program Project Grant (NIH-PPG) investigating the genetic and phenotypic basis of von Willebrand disease (VWD) in collaboration with colleagues based at the BloodCenter of Wisconsin, Milwaukee WI, USA (Prof. Robert Montgomery) and Queen’s University, Kingston ON, Canada (Prof. David Lillicrap). My contributions to this research field have led to me receiving International Society on Thrombosis and Haemostasis (ISTH) Young Investigator Awards (2009 and 2011), serving as co-chair of the ISTH Scientific and Standardization Committee on von Willebrand factor (2012-2015) and invitations to present my research at both national / international meetings (2010, 2015 and 2017). In addition, skills I developed relating to curation and interpretation of genetic variation data have led to roles with the European Association for Haemophilia and Allied Disorders and Human Variome Project (2011-present) helping to establish variant databases to provide researchers / clinicians with information on phenotype-genotype correlations.
My initial research associated with this NIH-PPG as a postdoctoral researcher has revealed a range of genetic mechanisms involved in the pathogenesis of the bleeding disorder VWD that result in quantitative deficiency or functional defects of the plasma glycoprotein von Willebrand factor (VWF). Recently, my role in this NIH-PPG has developed into a Senior Scientist as I have begun to design and supervise (in addition to conduct) my own research focused specifically on identifying genetic factors that may contribute to the unusually wide variation in VWF plasma levels observed in the general population. An increased understanding of the factors influencing VWF levels has important implications given that variation in VWF levels is associated with susceptibility to both bleeding (reduced VWF levels) and thrombosis (elevated levels). My research in this area has investigated the transcriptional regulation of the VWF gene and other genetic modifiers of VWF level including single nucleotide variants within the VWF locus previously thought to be ‘neutral’ common polymorphisms. Applying the knowledge and experience I have gained to date, I now aim to ascertain the role that natural variation in plasma VWF levels has in determining clinical outcomes following treatment in patients with acute coronary syndromes.
- Lead tutor for the Doctoral Development Programme (DDP) module MED640: ‘Critical review of research papers’.
- Deputy lead for the MRes in Cardiovascular Medicine module CDL602: ‘Research skills’.
- Lecturer on the undergraduate phase 1 MBChB Cardiovascular module.
- Database Manager for the von Willebrand factor Variant Database (VWFdb).
- Member of the European Association for Haemophilia and Allied Disorders Coagulation Factor Variant Databases (EAHAD-DB) Steering Group.
- Committee Member, Human Variome Project Gene / Disease Specific Database Advisory Council.
- Member of the ThromboGenomics Consortium.
- Postdoctoral Research Associate on an NIH funded PPG ‘Zimmerman Project on the Molecular and Clinical Biology of von Willebrand disease’.
Link to ORCID page here.
Mufti AH, Ogiwara K, Swystun LL, Eikenboom JCJ, Budde U, Hopman WM, Halldén C, Goudemand J, Peake IR, Goodeve AC, Lillicrap D & Hampshire DJ (2018) The common VWF single nucleotide variants c.2365A>G and c.2385T>C modify VWF biosynthesis and clearance . Blood Advances, 2(13), 1585-1594.
Cartwright A, Peake IR, Goodeve AC & Hampshire DJ (2016) In silico analysis highlights the copy number variation mechanism responsible for the historically reported VWF exon 42 deletion. Haemophilia, 22(5), e484-e487.
Hampshire DJ & Goodeve AC (2014) p.P2063S: a neutral VWF variant masquerading as a mutation. Ann Hematol, 93(3), 505-506.
Hampshire DJ, Abuzenadah AM, Cartwright A, Al-Shammari NS, Coyle RE, Eckert M, Al-Buhairan AM, Messenger SL, Budde U, Gürsel T, Ingerslev J, Peake IR & Goodeve AC (2013) Identification and characterisation of mutations associated with von Willebrand disease in a Turkish patient cohort. Thrombosis and Haemostasis, 110(2), 264-274.
Hampshire DJ & Goodeve AC (2011) The International Society on Thrombosis and Haematosis von Willebrand disease database: an update. SEMIN THROMB HEMOST, 37, 470-479.
Hampshire DJ & Goodeve AC (2011) The molecular basis of von Willebrand disease: the under investigated, the unexpected and the overlooked. HAEMATOLOGICA, 96, 798-800.
Hickson N, Hampshire D, Castaman G, Eikenboom J, Rodeghiero F, Peake I, Goodeve A & MCMDM-1VWD and ZPMCB-VWD Study Groups (2011) Effect of the VWF promoter (GT)n repeat and single-nucleotide polymorphism c.-2527G>A on circulating von Willebrand factor levels under normal conditions. Journal of Thrombosis and Haemostasis, 9(3), 603-605.
Hampshire DJ, Burghel GJ, Goudemand J, Bouvet LCS, Eikenboom JCJ, Schneppenheim R, Budde U, Peake IR, Goodeve AC & EU-VWD and ZPMCB-VWD study groups (2010) Polymorphic variation within the VWF gene contributes to the failure to detect mutations in patients historically diagnosed with type 1 von Willebrand disease from the MCMDM-1VWD cohort. HAEMATOLOGICA, 95, 2163-2165.
Othman M, Chirinian Y, Brown C, Notley C, Hickson N, Hampshire D, Buckley S, Waddington S, Parker AL, Baker A, James P & Lillicrap D (2010) Functional characterization of a 13-bp deletion (c.-1522_-1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease. BLOOD, 116, 3645-3652.
Hickson N, Hampshire D, Winship P, Goudemand J, Schneppenheim R, Budde U, Castaman G, Rodeghiero F, Federici AB, James P, Peake I, Eikenboom J, Goodeve A & MCMDM-1VWD and ZPMCB-VWD study groups (2010) von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels. Journal of Thrombosis and Haemostasis, 8(9), 1986-1993.
Ali S, Ghosh K, Daly ME, Hampshire DJ, Makris M, Ghosh M, Mukherjee L, Bhattacharya M & Shetty S () Congenital macrothrombocytopenia is a heterogeneous disorder in India. Haemophilia.